Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc. is a leading provider of behavioral healthcare services, headquartered in Franklin, Tennessee. Established in 2005, the company's mission is to deliver compassionate care that improves lives, inspires hope, and elevates communities, setting a standard of excellence in the treatment of mental health and addiction disorders.

Acadia Healthcare offers a comprehensive range of services across a network of facilities, including inpatient psychiatric hospitals, residential treatment centers, specialty treatment facilities, and outpatient clinics. These services address various behavioral health and substance use disorders, encompassing detoxification, acute psychiatric inpatient hospitalization, medication-assisted treatment (MAT), partial hospitalization programs (PHPs), intensive outpatient programs (IOPs), and traditional outpatient services. The company serves a broad demographic, from children and adolescents to adults and seniors, focusing on individuals with severe mental illness, substance use disorders, eating disorders, and co-occurring conditions.

As of March 31, 2026, Acadia Healthcare operated over 275 behavioral healthcare facilities with approximately 12,400 beds across 40 states and Puerto Rico, positioning itself as the largest stand-alone behavioral healthcare company in the U.S. Debbie K. Osteen serves as the Chief Executive Officer, with David Duckworth returning as Interim Chief Financial Officer in April 2026. The company recently reported strong first-quarter 2026 results, with revenue increasing by 7.6% to $828.8 million and earnings per share of $0.37, surpassing analyst expectations, though second-quarter guidance came in below consensus. Acadia is currently focused on operational execution and maximizing value from its existing facilities.

Latest updates

Acadia Healthcare Posts Modest Growth, Faces Regulatory and Cost Pressures

Event summary

  • Acadia Healthcare reported Q1 2026 revenue of $828.8 million, a 7.6% increase year-over-year.
  • Same-facility revenue grew 7.3%, driven by a 5.6% increase in revenue per patient day and a 1.6% increase in patient days.
  • Net income attributable to Acadia totaled $0.05 per diluted share, down from $0.09 in Q1 2025.
  • Adjusted EBITDA was $144.2 million, up from $134.2 million in the prior year, but adjusted EPS declined from $0.40 to $0.37.
  • The company added 82 new licensed beds during the quarter, including facilities from a joint venture with Tufts Medicine.

The big picture

Acadia's Q1 results highlight a slowing growth trajectory amidst a challenging regulatory landscape and rising operational costs within the behavioral healthcare sector. While the company benefited from supplemental payments in the prior year, the guidance for Q2 2026 suggests a more subdued outlook. The company's focus on efficiency and expansion, coupled with the return of Debbie Osteen as CEO, signals an attempt to stabilize performance and navigate these headwinds, but the long-term impact remains to be seen.

What we're watching

Regulatory Headwinds
The impact of the One Big Beautiful Bill Act (OBBBA) on Medicaid financing mechanisms will likely continue to pressure margins and patient volumes, requiring Acadia to adapt its service offerings and pricing strategies.
Cost Management
The company's ability to maintain Adjusted EBITDA growth will depend on its success in controlling operating expenses, particularly provider taxes and labor costs, which are facing upward pressure.
Execution Risk
The pace at which Acadia can integrate newly acquired facilities and expand existing capacity, as evidenced by the Tufts Medicine joint venture, will be crucial for driving future revenue growth and offsetting headwinds.

Acadia Healthcare CFO Departs for Animal Health, Former Exec Returns Interm

Event summary

  • David Duckworth, previously Acadia Healthcare's CFO (2012-2023), is returning as Interim CFO, effective May 1, 2026.
  • Todd Young is leaving Acadia to become CFO of a private equity-backed animal health company.
  • Young will participate in Acadia’s Q1 earnings call on April 30, 2026, and departs April 30, 2026.
  • Acadia is reaffirming its Q1 and full-year 2026 financial guidance.
  • Acadia operates 277 facilities with over 12,500 beds as of December 31, 2025.

The big picture

The departure of a CFO to a private equity-backed competitor signals potential shifts in the behavioral healthcare landscape, with increased focus on specialized niches like animal health. Acadia's reliance on government reimbursement, as highlighted by the OBBBA reference, makes it vulnerable to policy changes. The appointment of an interim CFO underscores the ongoing search for a permanent leader, which may delay strategic initiatives and create uncertainty for investors.

What we're watching

Governance Dynamics
The ongoing search for a permanent CEO, coupled with the interim CFO appointment, suggests continued instability at the executive level, potentially impacting strategic decision-making.
Regulatory Headwinds
The reaffirmed guidance references the One Big Beautiful Bill Act (OBBBA), indicating continued pressure on Medicaid financing mechanisms and potential revenue impacts.
Execution Risk
David Duckworth’s return as interim CFO may provide continuity, but the success of Acadia’s strategic priorities will depend on his ability to quickly re-engage and drive execution.
CID: 2547